4-AP对MPP+/MPTP诱导的帕金森病模型的影响
Qiongwen Rong1, Chang Zhou1, Yuanyuan Ma1
1Department of Neurology, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, 570102, China. 13907580113@163.com.
Cellular and molecular biology (Noisy-le-Grand, France)
|September 16, 2023
概括
4-阿米诺皮里丁 (4-AP) 没有改善帕金森病患者的运动功能.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,其特征是运动功能障碍.
- MPP+和MPTP是常用的神经毒素,用于诱导帕金森症模型在体外和体内.
- 4-阿米诺皮里丁 (4-AP) 是一种通道阻塞剂,具有潜在的神经保护作用.
研究的目的:
- 在帕金森病 (PD) 的细胞和动物模型中研究4-Aminopyridine (4-AP) 的治疗潜力.
- 在PD模型中评估4-AP对细胞活力,运动功能和多巴胺基神经元存活率的影响.
主要方法:
- 使用MPP+建立了帕金森病细胞模型,并使用不同度的4-AP进行治疗.
- 使用CCK8试验评估了细胞活力.
- 帕金森病小鼠模型被MPTP诱导,随后用4-AP治疗10天.
- 进行了行为测试 (杆登,露天) 和免疫组织化学 (IHC) /西斑 (WB) 对氨酸氧酶 (TH) 表达的测试.
主要成果:
- 4-AP增加了MPP+诱导的帕金森病细胞的活力.
- 在MPTP诱导的帕金森病小鼠中,4-AP与未经治疗的PD小鼠相比,没有改善自发活动或杆登时间.
- 与正常小鼠相比,PD小鼠和4-AP治疗的PD小鼠都显示中脑TH表达减少;4-AP没有阻止这种减少.
结论:
- 在细胞模型中,4-AP预处理可能会降低MPP+的毒性.
- 在MPTP诱导的帕金森病模型中,4-AP不会改善运动缺陷或保护多巴胺类神经元.
- 干预的时间 (治疗前与干预后) 对于帕金森病模型中的治疗疗效至关重要.
相关概念视频
Parkinson's Disease: Treatment
295
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
295
Parkinson's Disease: Overview
592
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
592


